Expanded Access for CC-4047

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

AMG 701 Expanded Access Program

NCT05256446 ·Status: NO_LONGER_AVAILABLE

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

NCT05757973 ·Status: APPROVED_FOR_MARKETING

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

NCT05238311 ·Status: NO_LONGER_AVAILABLE

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

NCT00179647 ·Status: COMPLETED ·Phase: PHASE3

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

NCT04036461 ·Status: TERMINATED ·Phase: PHASE1

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT04975399 ·Status: TERMINATED ·Phase: PHASE1

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916 ·Status: COMPLETED ·Phase: PHASE1

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

NCT00103506 ·Status: COMPLETED ·Phase: PHASE3

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00056160 ·Status: COMPLETED ·Phase: PHASE3

PHA-739358 for the Treatment of Multiple Myeloma

NCT00872300 ·Status: TERMINATED ·Phase: PHASE2

Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

NCT03126617 ·Status: NO_LONGER_AVAILABLE

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

NCT05503550 ·Status: NO_LONGER_AVAILABLE

Preemptive Strike With Bortezomib in Multiple Myeloma Patients

NCT00657553 ·Status: TERMINATED ·Phase: PHASE3

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

NCT00083876 ·Status: COMPLETED ·Phase: PHASE3

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

NCT00722566 ·Status: COMPLETED ·Phase: PHASE3

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

NCT00742560 ·Status: COMPLETED ·Phase: PHASE2

ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

NCT00440479 ·Status: COMPLETED

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

The Effect of High Dose Simvastatine on Multiple Myeloma

NCT00281476 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

NCT00216697 ·Status: COMPLETED ·Phase: PHASE2

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

NCT06183489 ·Status: RECRUITING ·Phase: PHASE2